Welcome to NorthStar’s newsroom
Filter Your Results
WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S. Food and Drug Administration (FDA) on the approval of the first domestically-produced, non-uranium based molybdenum-99 (Mo-99). Read more…
Today, I’m proud to acknowledge the role the FDA played in the groundbreaking effort to develop a new imaging technology – the RadioGenix System. Read more…
WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S. Food and Drug Administration (FDA) on the approval of the first domestically-produced, non-uranium based molybdenum-99 (Mo-99). Read more…
FDA Media Transcripts: https://www.fda.gov/NewsEvents/Newsroom/MediaTranscripts/default.htm Listen to FDA Media Briefing:
FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging. Read more…
NorthStar Medical Radioisotopes’ Radiogenix™ Isotope Separation System’s product packaging is convenient, intuitive, creative and unconventional. Read more…
According to NNSA, NorthStar Medical Radioisotopes is to receive $5.2 million to further develop its technology to produce Mo-99 via neutron capture, bringing the total NNSA support for the project to $16.1 million to date. Read more…
NorthStar also signed a similar agreement with Triad Isotopes, Inc. in June. Read more…
MADISON, Wis., Aug 14, 2014 (BUSINESS WIRE) — NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company GE, -0.42% marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). Read more…
Twelve years ago George Messina met with a scientist about a new patent that would likely change how medical diagnostic testing would be done in the United States. Read more…
BELOIT (WIFR) — One medical company is bringing more jobs to the Beloit area, but that may not be the biggest factor of the move. Read more…
BELOIT, Wis. – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Read more…
Everybody loves the entrepreneur, the little guy or gal with the big idea who launches and expands a business. Politicians of every stripe correctly tout start-up companies as key to creating more jobs. Read more…
What does it say about a state’s innovation-based economy when it boasts not one but two of the four U.S. companies racing to produce a medical isotope so essential that it’s used in 50,000 clinical tests per day? Read more…
WASHINGTON, D.C. – The National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative announced today the signing of a cooperative agreement with NorthStar Medical Radioisotopes, LLC, to further the development of accelerator-based technology to produce molybdenum-99 (Mo-99) in the United States. Read more…
NorthStar Medical Radioisotopes LLC said Tuesday it has signed a $4.6 million agreement with the National Nuclear Security Administration that will help the Madison company develop architectural and site plans for a Beloit plant to produce medical isotopes. Read more…
As problems go, NorthStar Medical Radioisotopes LLC was founded on a big one. Production issues at several nuclear power plants outside the U.S. during the last few years and worries about nuclear proliferation prompted the federal government in 2009 to look for ways to make a critical medical isotope more safely and closer to home. Read more…
NorthStar Medical Radioisotopes has entered a tentative deal with GE Hitachi Nuclear Energy and Exelon for the production of the medical isotope molybdenum-99. Read more…
NorthStar Medical Radioisotopes LLC, a Madison nuclear medicine company, has signed a tentative agreement for its Beloit facility to process radioactive material into a key isotope used for medical procedures. Read more…
MADISON, Wis.–(BUSINESS WIRE)–Six Wisconsin bioscience companies have been selected as the winners of BioForward’s 2011 Emerging Company Showcase. Read more…
NorthStar Medical Radioisotopes, LLC plans to locate a new 82,000 square foot production facility in Beloit. Read more…
NorthStar Medical Radioisotopes LLC is planning to build a $194 million production plant in Beloit that could employ as many as 150 people by 2016. Read more…
NorthStar Medical Radioisotopes, Madison, will build an 82,000-square-foot manufacturing plant in Beloit. Read more…
NorthStar Medical Radioisotopes LLC is planning to build a $194 million production plant in Beloit that could employ as many as 150 workers by 2016. Read more…
A highly-specialized company serving the needs of the nuclear medicine market plans to locate its $194 million, 82,000-square foot production facility in Beloit. Read more…
Filter Your Results
BELOIT, Wis. – June 19, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in a panel session on molybdenum-99 (Mo-99) supply at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 23
BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program. Ac-225 is a high energy alpha-emitting radioisotope with potential therapeutic applications as a Targeted Alpha Therapy (TAT)
– Event recognizes recent U.S. Food and Drug approval of NorthStar’s RadioGenix™ System for use in producing the widely used medical isotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99), the first domestic production in more than 25 years – BELOIT, Wis. – April 30, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved
– Enables domestic Mo-99 supply produced without uranium for U.S. healthcare – – First U.S. source of medical radioisotope Mo-99 in more than 25 years – BELOIT, Wis. – February 8, 2018 – NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food
Holst has more than 25 years of sales and marketing experience in the pharmaceutical and medical imaging industries, most recently as senior director of marketing at Navidea Biopharmaceuticals. She joins NorthStar as it advances toward U.S. Food and Drug Administration (FDA) approval of its RadioGenix™ intelligent isotope separation system and its non-fission, non-uranium-based brand of
BELOIT, Wis. – NorthStar Medical Technologies LLC, parent company of NorthStar Medical Radioisotopes LLC, has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), bringing to $11.1 million the total funded for NorthStar Medical Radioisotopes’ accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The award supports the process’
ST. LOUIS (Sept. 13, 2016) – At the National Nuclear Security Administration’s (NNSA) 2016 Mo-99 Topical Meeting in St. Louis, NorthStar Medical Radioisotopes LLC Senior Vice President and Chief Science Officer James Harvey, Ph.D. will report on the company’s progress toward establishing a domestic supply of the medical radioisotope molybdenum-99 (Mo-99) produced without the use
BELOIT, Wis. (Sept. 12, 2016) – NorthStar Medical Radioisotopes LLC has hired James Brodack as vice president of regulatory affairs/quality assurance and Rim Milunas as vice president of engineering. Brodack oversees day-to-day regulatory and quality operations at NorthStar. Milunas spearheads research and development. product design and engineering, with a strong focus on product development and
BELOIT, Wis. (June 10, 2016) – NorthStar Medical Radioisotopes LLC has been awarded three patents and a trademark approval from the United States Patent and Trademark Office. Patents were granted for the RadioGenix™ isotope separation system and two of its key components – the Molybdenum-99 (Mo-99) Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge. A
BELOIT, Wis. – NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Missouri, adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99). NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include
BELOIT, Wis. – Stephen Merrick has joined NorthStar Medical Radioisotopes LLC as Senior Vice President and Chief Operating Officer, a newly created position with the company. Merrick brings 24 years of experience in the biotechnology/pharmaceutical/life sciences sector, having held multiple executive positions with leading global companies. He will oversee day-to-day operations at NorthStar – including engineering, production and customer
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received $11.75 million from the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) for continued development and commercialization of two technologies to produce the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). NNSA provided $8.86 million to support NorthStar’s neutron capture production process and $2.89 million for the company’s accelerator production process.
MADISON, Wis. – NorthStar Medical Radioisotopes LLC and the Westinghouse Electric Company LLC have completed a memorandum of understanding under which the companies will explore the potential for producing medical radioisotopes in commercial nuclear reactors. Of particular interest is the generation of molybdenum-99 (Mo-99) via the irradiation of molybdenum-98 (Mo-98) in the commercial nuclear reactor core. This collaboration is
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo. The company will now be able regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has completed its first production-scale test run of the molybdenum-99 (Mo-99) aliquoting system installed at the University of Missouri Research Reactor (MURR) in Columbia, Missouri. The test and subsequent shipment of the resulting Mo-99 to NorthStar’s Madison facility is another milestone in the establishment of domestic production of the vital medical radioisotope.
MADISON, Wis. – James Harvey, Ph.D., senior vice president and chief science officer of NorthStar Medical Radioisotopes LLC, will be a featured speaker at the American Pharmacists Association Annual Meeting & Exposition (APhA2015) in San Diego later this month, highlighting new technologies and techniques that will create a commercially viable domestic supply of the medical radioisotope molybdenum-99 (Mo-99). Harvey
MADISON, Wis. – NorthStar Medical Radioisotopes LLC has been awarded $5.2 million in additional funding by the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The grant supports the continued development and commercialization of the company’s neutron capture process for producing the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Under the terms of the cooperative agreement
Madison, Wis. – August 14, 2014 – NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company (NYSE: GE), marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). 99Mo is the parent isotope of 99mtechnetium (99mTc), the most widely
BELOIT, Wis. – July 22, 2014 – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Video Courtesy WKOW News NorthStar Medical Radioisotopes Breaks Ground
WASHINGTON, D.C. – July 15, 2014 – NorthStar Medical Radioisotopes LLC is making continued progress towards establishing a commercially viable domestic supply of the radioisotope molybdenum-99 (Mo-99), according to NorthStar’s chief science officer, James T. Harvey, Ph. D. Harvey provided an update on NorthStar’s progress in two presentations at the 2014 Mo-99 Topical Meeting here,
MADISON, Wis. – June 30, 2014 – NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO) designed to help the CTBTO detect nuclear testing. In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission
ST. LOUIS, MO – June 7, 2014 – Signaling progress in the drive to launch the first commercially-viable domestic source of non-HEU materials, NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc. The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through
MADISON, WI – November 21, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), today announced it was awarded a $21.8 million cooperative agreement of which $10.9 million will be funded by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The cooperative agreement is part of the NNSA’s Global Threat Reduction Initiative, which aims to
MADISON, WI – September 17, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine industry, today announced the closing of a financing round totaling $13.5 million. The round was led by NorthStar’s lead investor, Hendricks Holding Company, Inc., and a group of accredited local investors. Proceeds
MADISON, WI – March 20, 2013 – NorthStar Medical Technologies, LLC, (NorthStar) announced that it has submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA). The FDA has accepted the application for review. The submission is for NorthStar’s TechneGen™ Generator System, which will allow nuclear pharmacies to process radioisotopes for critical medical
MADISON, WI. – November 15, 2012 – NorthStar Medical Radioisotopes, LLC (NorthStar), today announced that it has been awarded $22.2 million in federal funding in a Phase 2 cooperative agreement through the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative. The cooperative agreement marks successful completion of an Environmental Assessment of NorthStar’s proposed Beloit, Wis. facility.
MADISON, WI – September 26, 2012 – NorthStar Medical Technologies, LLC (NorthStar), today announced that it has signed an agreement with Hendricks Commercial Properties, LLC (HCP) to develop a state-of-the-art medical isotope production facility in the Gateway Business Park of Beloit, Wisconsin. The facility will be built to suit for lease. Once complete, the facility
MADISON, WI – September 5, 2012 – NorthStar Medical Technologies, LLC (NorthStar), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine field, today announced the closing of a Series D preferred stock financing round totaling $5.2 million. Stateline Angel Investors of Rockford, Illinois, was the lead investor, joined by existing NorthStar investor Hendricks
(MADISON, Wis. – Nov. 1, 2011) – NorthStar Medical Radioisotopes, LLC (NMR) has signed a follow on cooperative agreement totaling $4.6 million with the National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative for the company’s medical isotope production program. The cooperative agreement will be funded under a 50-50 cost share arrangement between NMR and
WILMINGTON, N.C.—September 12, 2011—To help address a shortage of molybdenum-99 (Mo-99), a medical isotope used in millions of medical procedures each year, GE Hitachi Nuclear Energy (GEH) and Exelon have joined to study the feasibility of producing Mo-99 at Clinton Power Station, a nuclear power plant in Clinton, Ill. Mo-99 decays into technetium-99m, an isotope
MADISON, Wis. –Sept. 8 — NorthStar Medical Radioisotopes was among six Wisconsin bioscience companies to be selected as the winners of BioForward’s 2011 Emerging Company Showcase. The showcase is part of the 2011 Bioscience Vision Summit, hosted by BioForward, the member-driven state association that is the voice of Wisconsin’s bioscience industry. The Emerging Company Showcase
(MADISON, WI. – April 7, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has received an investment from Hendricks Holdings of Beloit, WI. The investment will allow NorthStar to rapidly pursue introduction of new technologies and production methodologies in the nuclear medicine market for molybdenum-99 and other medically significant radioisotopes. Molybdenum-99 is used to
(MADISON, WI. – March 1, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has signed an agreement with the University of Missouri Research Reactor (MURR) to supply NorthStar with low specific activity molybdenum-99. This agreement allows NorthStar to ramp up over time to 3,000 6-day curies per week. Production operations are expected to begin
Questions?
Do you have questions about NorthStar, our products, supply solutions, careers or anything else?
